|
Title
|
|
|
|
Tackling chronic inflammation with withanolide phytochemicals : a Withaferin A perspective
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Chronic inflammatory diseases are considered to be one of the biggest threats to human health. Most prescribed pharmaceutical drugs aiming to treat these diseases are characterized by side-effects and negatively affect therapy adherence. Finding alternative treatment strategies to tackle chronic inflammation has therefore been gaining interest over the last few decades. In this context, Withaferin A (WA), a natural bioactive compound isolated from Withania somnifera, has been identified as a promising anti-cancer and anti-inflammatory compound. Although the majority of studies focus on the molecular mechanisms of WA in cancer models, recent evidence demonstrates that WA also holds promise as a new phytotherapeutic agent against chronic inflammatory diseases. By targeting crucial inflammatory pathways, including nuclear factor kappa B (NF-κB) and nuclear factor erythroid 2 related factor 2 (Nrf2) signaling, WA suppresses the inflammatory disease state in several in vitro and preclinical in vivo models of diabetes, obesity, neurodegenerative disorders, cystic fibrosis and osteoarthritis. This review provides a concise overview of the molecular mechanisms by which WA orchestrates its anti-inflammatory effects to restore immune homeostasis. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Antioxidants
| |
|
Publication
|
|
|
|
2020
| |
|
ISSN
|
|
|
|
2076-3921
| |
|
DOI
|
|
|
|
10.3390/ANTIOX9111107
| |
|
Volume/pages
|
|
|
|
9
:11
(2020)
, 17 p.
| |
|
Article Reference
|
|
|
|
1107
| |
|
ISI
|
|
|
|
000592910600001
| |
|
Pubmed ID
|
|
|
|
33182809
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|